This review summarizes the complex pathophysiological mechanisms of aortic stenosis and highlights the current lack of effective pharmacological treatments for early-stage disease.
Answers are grounded in this paper and cite their sources.
No approved drugs slow early aortic stenosis; leaves open mechanism-targeted trials on calcification and inflammation.
Aortic stenosis (AS) represents the most common type of acquired valvular heart disease. Its incidence increases with age; therefore, from 3% to 9% of adults over 75 years of age develop AS. The pathophysiological mechanisms and role of biomarkers in the prediction of AS have been extensively studied. Progression of AS is characterized by a number of abnormalities in calcification regulation, inflammation/adipokine dysregulation, prothrombic state, and altered von Willebrand factor function. The current understanding of the mechanisms of AS involves a complex role of the multiple cell types, in particular myofibroblasts and macrophages. The introduction of transcatheter aortic valve implantation provides invaluable opportunities for periprocedural and long-term monitoring of the changes in the biomarker profile. Effective pharmacological treatment, especially in the early stage of AS, is largely unknown. The current review discusses not only the pathophysiology of AS but also attempts at pharmacological treatment.
No takes yet. Share an insight, caveat, or question.
Paweł Petkow Dimitrow (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: